Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
7.15 USD +0.42% Intraday chart for Candel Therapeutics, Inc. -19.66% +386.39%
May. 30 FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma MT
May. 30 Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment DJ

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating
MT
UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating
MT
Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating
MT
HC Wainwright Starts Candel Therapeutics at Buy With $11 Price Target
MT
BMO Capital Adjusts Candel Therapeutics' Price Target to $12 from $18, Keeps Outperform Rating
MT
BMO Initiates Candel Therapeutics With Outperform Rating, $18 Price Target
MT
Candel Therapeutics : Shares Rise After Analyst Recommendations
MT
CANDEL THERAPEUTICS : Credit Suisse Starts Candel Therapeutics at Outperform with $15 PT, Notes Potential for Improved Investor Sentiment, Valuation
MT
CANDEL THERAPEUTICS : UBS Starts Candel Therapeutics at Buy With $9 Price Target
MT
CANDEL THERAPEUTICS : Jefferies Starts Candel Therapeutics at Buy With $22 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CADL Stock
  4. News Candel Therapeutics, Inc.
  5. Analyst Reco.